A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples
NCT ID: NCT02189330
Last Updated: 2014-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2014-05-31
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)
NCT03662191
A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
NCT02746926
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
NCT03280173
A Study to Learn How Different Forms of Study Medicine Tafamidis Are Taken Up Into The Blood in Healthy Adults
NCT06273839
A Study to Compare Two Tablet Forms of Tafamidis in Healthy Participants
NCT05482308
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tafamidis
Tafamidis
20 mg of current commercial formulation.
Tafamudus Free Acid
Tafamidis
12.2 mgA free acid tablet.
20 mg new soft gelatin capsule
Tafamidis
20 mg new soft gelatin capsule.
4 capsules of 20 mg tafamidis of commercial formulation
Tafamidis
4 capsules of 20 mg tafamidis of current commercial formulation.
4 capsules of 12.2 mg tafamidis of free acid tablet
Tafamidis
4 capsules of 12.2 mg tafamidis of free acid tablet..
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tafamidis
20 mg of current commercial formulation.
Tafamidis
12.2 mgA free acid tablet.
Tafamidis
20 mg new soft gelatin capsule.
Tafamidis
4 capsules of 20 mg tafamidis of current commercial formulation.
Tafamidis
4 capsules of 12.2 mg tafamidis of free acid tablet..
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index (BMI) of 17.5 to 30.5 and total body weight more than 50 kg (110 lbs).
Exclusion Criteria
* Use of prescription or nonprescription drugs supplements within 7 days prior to 7 days of the study.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Brussels, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B3461030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.